Abbott’s AdviseDx SARS-CoV-2 IgM Test Receives the US FDA’s EUA for COVID-19
Abbott’s AdviseDx SARS-CoV-2 IgM Test Receives the US FDA’s EUA for COVID-19
Shots:
- Abbott has received the US FDA’s EUA for AdviseDx SARS-CoV-2 IgM lab-based serology test for use on the ARCHITECT and Alinity platforms
- Till now, Abbott has received EUA for its seven tests, including molecular tests, a rapid antigen test and, an IgG Ab test for COVID-19
- The IgM test demonstrated 99.56% specificity and 95.00% sensitivity for patients tested 15 days after symptom onset. The test will give a more complete picture of where patients are in their recovery
Click here to read full press release/ article | Ref: Abbott | Image: Medical Device and Diagnostic Industry